No insider purchase over the last 90 days. The latest, by Flynn James P, was filed 25 Jun 2026.
Lite Strategy, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 24 October 2025 to 24 October 2026, the disclosure feed for Lite Strategy, Inc. logged 4 filings by 2 insiders.
On the market, 1 insider bought (3 purchases totalling €122k) while 1 insider sold (1 sale totalling €806k). Netting one side against the other leaves €684k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a sale of €806k by Schornstein Alexander, published on 22 December 2025. The buyers include 1 senior executive.
With 4 filings in twelve months, the company is quieter than the median of 24 filings across the 3,169 companies we follow on the same exchange. Over the whole record (from 2008), the tally stands at 40 purchases and 38 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 30 June 2025 lists net income at -15.9 m USD.
The last insider purchase was made public on 25 June 2026, 121 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended June 2025 · cache
25 of 111 declarations
Lite Strategy, Inc. is a company listed on the XNAS market. It specializes in developing strategic solutions for businesses.
Purchases our model currently ranks for the recommendations list.
All recommendations| Fiscal year end | Revenue | Net income | Diluted EPS | Dividend per share | Filing |
|---|---|---|---|---|---|
| Jun 2025 | n.d. | -15.9 m USD | -2.39 USD | n.d. | 10-K |
| Jun 2024 | 65.3 m USD | 18.0 m USD | 2.67 USD | 1.75 USD | 10-K |
| Jun 2023 | 48.8 m USD | -32.0 m USD | -4.78 USD | n.d. | 10-K |
| Jun 2022 | 40.7 m USD | -54.0 m USD | -9.99 USD | n.d. | 10-K |
| Jun 2021 | 34.8 m USD | -41.0 m USD | -0.60 USD | n.d. | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.